28 Jan 2022 by admin in UncategorizedComments Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings
17 Jan 2022 by admin in UncategorizedComments Eluminex Biosciences Successfully Completes Its First Pre-IND Meeting with the United States Food and Drug Administration for a Multivalent Fc Fusion Protein (EB-101) for the Treatment of Neovascular Age-related Macular Degeneration
10 Jan 2022 by admin in UncategorizedComments Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company
10 Jan 2022 by admin in UncategorizedComments BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies
05 Jan 2022 by admin in UncategorizedComments Eluminex Further Expands Leadership Team and Receives New Awards
